Search

Your search keyword '"Lecrubier, Y"' showing total 629 results
Start Over Author "Lecrubier, Y"
629 results on '"Lecrubier, Y"'

3. Establishing non-inferiority in treatment trials in psychiatry -guidelines from an Expert Consensus Meeting

Author

Nutt, D., Allgulander, C., Lecrubier, Y., Peters, T., and Wittchen, U.

Subjects
Venlafaxine -- Testing, Generalized anxiety disorder -- Drug therapy, Clinical trials -- Management, Pharmaceuticals and cosmetics industries, Psychology and mental health, Company business management, Management, Drug therapy, Testing
Abstract

Byline: D. Nutt (Psychopharmacology Unit, University of Bristol, Bristol, UK, david.j.nutt@bristol.ac.uk); C. Allgulander (Karolinska Institute, Karolinska University Hospital Huddinge, Huddinge, Sweden); Y. Lecrubier (La Salpetriere Pavillon Clerambault, Boulevard de l'Hopital, [...]

Published
2008
Full Text
View/download PDF

11. Negative symptoms in schizophrenia: considerations for clinical trials: Working group on negative symptoms in schizophrenia

Author

Möller, H. -J., van Praag, H. M., Aufdembrinke, B., Bailey, P., Barnes, T. R. E., Beck, J., Bentsen, H., Eich, F. X., Farrow, L., Fleischhacker, W. W., Gerlach, J., Grafford, K., Hentschel, B., Hertkorn, A., Heylen, S., Lecrubier, Y., Leonard, J. P., McKenna, P., Maier, W., Pedersen, V., Rappard, A., Rein, W., Ryan, J., Sloth Nielsen, M., Stieglitz, R. -D., Wegener, G., and Wilson, J.

Published
1994
Full Text
View/download PDF

29. Depressed subjects unwittingly overreport poor social adjustment which they reappraise when recovered

Author

Morgado, A., Smith, M., Lecrubier, Y., and Widlocher, D.

Subjects
Depression, Mental -- Complications, Psychotherapy patients -- Surveys, Social adjustment -- Psychological aspects, Social adjustment -- Measurement, Perception -- Psychological aspects, Psychology and mental health
Abstract

When patients are acutely depressed, there is the potential that their symptomatology will lead to bias when they report social maladjustment. That is, depressed people may report greater social maladjustment if questioned while they are depressed than they will report for the same period if they are not depressed. Using a test-retest design, this hypothesis was tested with patients who were hospitalized for depression. Prior to treatment, social maladjustment in 25 subjects was measured for the four-month period prior to hospitalization using a structured interview. Depressive symptoms were measured as well so that improvements after treatment, if apparent, could be ascertained. After the initial evaluation, patients were given antidepressant drugs for an average of 19.5 days. Not all patients responded to drug treatment; only the responders were re-evaluated. Overall, the scores obtained during the social maladjustment interviews prior to treatment were significantly higher than the scores obtained after treatment. These patients reported more social maladjustment when questioned during an acute phase of depression than when questioned in a non-depressed state about the same period of time. When patient self-assessments were compared with more objective ratings of social maladjustment, the reports of patients in the non-depressed state were more accurate. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

37. A psychopharmacological treatment algorithm for generalised anxiety disorder

Author

Davidson, J.R., Zhang, W., Connor, K.M., Ji, J., Jobson, K., Lecrubier, Y., McFarlane, A.C., Newport, D.J., Nutt, D.J., Osser, D.N., Stein, D.J., Stowe, Z.N., Tajima, O., and Versiani, M.

Subjects
Generalized anxiety disorder -- Diagnosis, Generalized anxiety disorder -- Care and treatment, Psychopharmacology -- Research, Practice guidelines (Medicine), Pharmaceuticals and cosmetics industries, Psychology and mental health
Published
2010

38. Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression

Author

Serretti, A, Chiesa, A, Crisafulli, C, Massat, I, Linotte, S, Calati, R, Kasper, S, Bailer, U, Lecrubier, Y, Fink, M, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, Souery, D, Mendlewicz, J, Serretti A, Chiesa A, Crisafulli C, Massat I, Linotte S, Calati R, Kasper S, Bailer U, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J, Serretti, A, Chiesa, A, Crisafulli, C, Massat, I, Linotte, S, Calati, R, Kasper, S, Bailer, U, Lecrubier, Y, Fink, M, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, Souery, D, Mendlewicz, J, Serretti A, Chiesa A, Crisafulli C, Massat I, Linotte S, Calati R, Kasper S, Bailer U, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, and Mendlewicz J

Abstract

In the present study, we aimed to confirm the previous finding of an association between GRIK4 and GNB3 variants (rs195478 and rs5443) and remission and treatment resistance in major depression, using a multicenter sample of 223 patients. We did not find any supporting evidence for such associations. These conflicting data may result from difficulties in the replication of candidate gene association studies. Copyright (C) 2012 S. Karger AG, Basel

Published
2012

39. No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression

Author

Serretti, A, Chiesa, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Fink, M, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, Souery, D, Mendlewicz, J, Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J, Serretti, A, Chiesa, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Fink, M, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, Souery, D, Mendlewicz, J, Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, and Mendlewicz J

Abstract

In the present study, aimed at investigating whether a set of single nucleotide polymorphisms (SNPs) within PTGS2 gene (rs4648276, rs2066826 and rs689466) could be associated with antidepressant response, remission and treatment resistance in a sample of major depression patients, we did not find evidence supporting any of such associations. © 2010 Elsevier Ltd.

Published
2011

40. Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression

Author

Souery, D, Serretti, A, Calati, R, Oswald, P, Massat, I, Konstantinidis, A, Linotte, S, Bollen, J, Demyttenaere, K, Kasper, S, Lecrubier, Y, Montgomery, S, Zohar, J, Mendlewicz, J, Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Zohar J, Mendlewicz J, Souery, D, Serretti, A, Calati, R, Oswald, P, Massat, I, Konstantinidis, A, Linotte, S, Bollen, J, Demyttenaere, K, Kasper, S, Lecrubier, Y, Montgomery, S, Zohar, J, Mendlewicz, J, Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Zohar J, and Mendlewicz J

Abstract

Objective: The management of treatment-resistant depression is a much debated issue. In particular, the evidence supporting the commonly suggested sequential use of antidepressants from 2 different pharmacological classes is weak.This retrospective study was undertaken to investigate whether there is a better response in nonresponders switched to a different class of antidepressants (across-class) compared with nonresponders switched to an antidepressant from the same class (within-class). Methods: Three hundred forty patients with primary major depressive disorder were recruited in the context of a European multicenter project. Subjects whose current depressive episode had failed to respond to a first antidepressant trial of adequate dose and duration were included. Results: There was no significant difference in response or remission rates between the across-class and within-class groups after controlling for possible confounders. Conclusions: In depressed nonresponders to a previous antidepressant treatment, switching to a different class of antidepressants was not associated with a better response or remission rate. © 2011 Lippincott Williams & Wilkins.

Published
2011

41. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression

Author

Serretti, A, Chiesa, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, Souery, D, Mendlewicz, J, Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J, Serretti, A, Chiesa, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, Souery, D, Mendlewicz, J, Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, and Mendlewicz J

Abstract

Background: The transcription factor Cyclic adenosine monophosphate Response Element Binding (CREB) protein has been repeatedly involved in the aetiology and pharmacotherapy of major depression (MD). The aim of this study was to investigate the potential association of a set of single nucleotide polymorphisms (SNPs) in CREB1 gene and both MD and response, remission and treatment resistance to antidepressants. Methods: One hundred-ninety MD patients collected in the context of a resistant depression study and treated with antidepressants for at least 4 weeks were genotyped for 5 CREB1 SNPs (rs2709376, rs2253206, rs7569963, rs7594560, and rs4675690). Response, remission and treatment resistance were recorded. Results: An allele of rs7569963 as well as rs2253206-rs7569963 A-A and rs7569963-rs4675690 A-C haplotypes were associated with the status of treatment resistance. Additionally, rs7569963 GG genotype was positively associated with remission. No further significant associations were observed. Limitations: Limitations of the present study include a relatively small sample size and the incomplete ascertainment of data which could influence the outcome. Conclusions: Our results preliminary suggest that some genetic polymorphisms in CREB1 could be associated to treatment resistance. Although such finding needs to be replicated in larger samples, it increases current knowledge about the genetic predictors of response to antidepressants that will probably lead to enhance treatment outcomes by addressing each individual to the most appropriate treatment strategy in the early stages of treatment. (C) 2010 Elsevier B.V. All rights reserved.

Published
2011

42. A preliminary investigation of CREB1 and PTGS2 polymorphisms on treatment resistance in major depression

Author

Serretti, A, Chiesa, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, D., M, J, Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D Souery, D. Mendlewicz, Serretti, A, Chiesa, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, D., M, J, Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D Souery, and D. Mendlewicz

Published
2010

43. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

Author

Serretti, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Sens-Espel, R, Bollen, J, Zohar, J, Berlo, J, Lienard, P, De Ronchi, D, Mendlewicz, J, Souery, D, Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D, Serretti, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Sens-Espel, R, Bollen, J, Zohar, J, Berlo, J, Lienard, P, De Ronchi, D, Mendlewicz, J, Souery, D, Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, and Souery D

Abstract

Cytochrome P450 genes are involved in the metabolism of antidepressants and could influence treatment response. The aim of this study was to investigate the role of allelic variations of the cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes in antidepressant treatment response and remission rates. Two hundred and seventy-eight patients affected by major depression, responders (N=81) and nonresponders (N=197) to at least one adequate antidepressant treatment, were recruited with a multicentre design for resistant depression and genotyped for all relevant variations. None of the considered metabolic profiles (e.g. poor, intermediate, extensive and ultrarapid metabolizers) was found to be associated with either response or remission rates. In conclusion, the investigated cytochrome genes do not seem to play a major role in antidepressant response in the present sample of depressive patients. Nevertheless, methodological and sample size limitations of this study do not allow definitive conclusions. Int Clin Psychopharmacol 24:250-256 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Published
2009

44. A preliminary investigation of CREB1 and PTGS2 polymorphisms on treatment resistance in major depression

Author

Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D Souery, D. Mendlewicz, J, Serretti, A, Chiesa, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, D., M, and J

Subjects
Genetics, treatment resistance, major depression
Published
2010

45. Amisulpride: Progress and Outcomes

Author

Lecrubier Y

Subjects
medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Atypical antipsychotic, Receptors, Dopamine, Basal Ganglia Diseases, Extrapyramidal symptoms, Internal medicine, Brief Psychiatric Rating Scale, medicine, Humans, Amisulpride, Psychiatry, Antipsychotic, Risperidone, business.industry, General Medicine, medicine.disease, Treatment Outcome, Schizophrenia, Quality of Life, Clinical Global Impression, Sulpiride, medicine.symptom, business, Antipsychotic Agents, medicine.drug
Abstract

Amisulpride is a unique atypical antipsychotic that selectively blocks D2 and D3 receptors presynaptically in the frontal cortex, possibly enhancing dopaminergic transmission, and postsynaptically in the limbic areas, possibly reducing it. Thus dopaminergic over-activity in the frontal cortex, and under-activity in the limbic areas, can be treated simultaneously, alleviating both positive and negative symptoms of schizophrenia, respectively. In acute schizophrenia, amisulpride is at least as effective as haloperidol, with a greater number of patients responding to treatment as determined by Clinical Global Impression (CGI scores (p = 0.014). In addition, amisulpride is associated with a lower incidence of extrapyramidal symptoms (EPS) as determined by Simpson-Angus scores (SAS) when compared with haloperidol (p = 0.0053). Amisulpride showed similar efficacy to risperidone as determined by the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Symptom Score (PANSS) positive subscale; a trend towards greater improvement of negative symptoms as determined by PANSS negative subscale compared with risperidone; and similar levels of EPS. Amisulpride uniquely benefits patients with negative symptoms and is the only antipsychotic to demonstrate efficacy in patients with predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium/long-term treatment as demonstrated in studies of up to 12 months. Amisulpride demonstrates greater improvement in controlling symptoms compared to haloperidol. In terms of the relevance of the effects, a superiority is observed for quality of life, social adaptation and functioning as measured by the Quality of Life Scale (QLS), Clinical Glocal Impression scale (CGI) and Functional Status Questionnaire (FSQ) scales. Amisulpride also has one of the lowest potentials of all the antipsychotic agents for weight gain. The clinical evidence for amisulpride supports its earlier pre-clinical potential, showing it to be an atypical antipsychotic agent with specific clinical advantages.

Published
2002
Full Text
View/download PDF

47. COMT and age at onset in mood disorders: a replication and extension study

Author

Massat, I, Kocabas, Na, Crisafulli, Concetta, Chiesa, A, Calati, R, Linotte, S, Kasper, S, Lecrubier, Y, Fink, M, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, Souery, D, Serretti, A, Mendlewicz, J., Massat I., Kocabas N.A., Crisafulli C., Chiesa A., Calati R., Linotte S., Kasper S., Fink M., Antonijevic I., Forray C., Snyder L., Bollen J., Zohar J., De Ronchi D., Souery D., Serretti A., Mendlewicz J., Massat, I, Kocabas, N, Crisafulli, C, Chiesa, A, Calati, R, Linotte, S, Kasper, S, Fink, M, Antonijevic, I, Forray, C, Snyder, L, Bollen, J, Zohar, J, De Ronchi, D, Souery, D, Serretti, A, and Mendlewicz, J

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Genotype, early onset, Catechol O-Methyltransferase, Polymorphism, Single Nucleotide, Polymorphism (computer science), Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Bipolar disorder, Allele, Age of Onset, Psychiatry, gene, Depression (differential diagnoses), Alleles, Early onset, Depressive Disorder, Major, General Neuroscience, BIPOLAR DISORDER, Middle Aged, medicine.disease, DEPRESSION, COMT, Mood disorders, Female, Psychology, rs4680
Abstract

Our study aims at replicating our previous finding of an association between COMT rs4680 G/A polymorphism and early onset major depression (MD). We included 462 MD, 147 bipolar disorders (BD) subjects and 295 healthy controls. We could partially replicate previous findings. In particular, rs4680 GG + AG genotypes were more represented in the subgroup of early onset MD patients (p = 0.04). Additionally, we observed an association between rs737865 alleles and early onset MD (p = 0.04). Rs4680 genotype was associated with early onset BD as well (p = 0.01). In conclusion, we partially replicated our previous findings confirming a possible influence of COMT variants in MD and BD, particularly in early onset subjects, though not with the same risk genotypes. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

Published
2011

49. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety

Author

Jc, Ballenger, Jr, Davidson, Lecrubier Y, Dj, Nutt, Td, Borkovec, Rickels K, Dj, Stein, and Hans-Ulrich Wittchen

Subjects
Depressive Disorder, Treatment Outcome, Cognitive Behavioral Therapy, Humans, Comorbidity, Age of Onset, Anxiety Disorders, Antidepressive Agents
Abstract

To provide primary care clinicians with a better understanding of management issues in generalized anxiety disorder (GAD) and guide clinical practice with recommendations on the appropriate treatment strategy.The 4 members of the International Consensus Group on Depression and Anxiety were James C. Ballenger (chair), Jonathan R.T. Davidson, Yves Lecrubier, and David J. Nutt. Four additional faculty members invited by the chair were Karl Rickels, Hans-Ulrich Wittchen, Dan J. Stein, and Thomas D. Borkovec.The consensus statement is based on the 6 review articles that are published in this supplement and the scientific literature relevant to the issues reviewed in these articles.Group meetings were held over a 2-day period. On day 1, the group discussed the review articles and the chair identified key issues for further debate. On day 2, the group discussed these issues to arrive at a consensus view. After the group meetings, the consensus statement was drafted by the chair and approved by all attendees.GAD is the most common anxiety disorder in primary care and is highly debilitating. Furthermore, it is frequently comorbid with depression and other anxiety disorders, which exacerbates functional impairment. Antidepressants (serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and nonsedating tricyclic antidepressants) are generally the most appropriate first-line pharmacotherapy for GAD, since they are also effective against comorbid psychiatric disorders and are suitable for long-term use. Cognitive-behavioral therapy is the preferred form of psychotherapy for GAD, although when GAD is comorbid with depression, pharmacotherapy is increasingly indicated.

Published
2001

50. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder

Author

Bauer, M, Whybrow, PC, Angst, J, Versiani, M, Möller, HJ, Allain, H, Anderson, I, Ayuso-Gutierrez, JL, Baldwin, D, Bech, P, Benkert, O, Berk, Michael, Bitter, I, Bourgeois, ML, Burrows, G, Cassano, G, Cetkovich-Bakmans, M, Cookson, JC, Costa, DD, Gheroghe, MD, Heinze, G, Higuchi, T, Hirschfeld, RM, Höschl, C, Holsboer-Trachsler, E, Kasper, S, Katona, C, Keller, MB, Kulhara, P, Kupfer, DJ, Lecrubier, Y, Leonard, B, Licht, RW, Lingjaerde, O, Lublin, H, Mendlewicz, J, Mitchell, P, Paykel, ES, Puzynski, S, Rush, AJ, Rybakowski, JK, Schweitzer, I, Unützer, J, Verstergaard, P, Vieta, E, Yamada, K, Bauer, M, Whybrow, PC, Angst, J, Versiani, M, Möller, HJ, Allain, H, Anderson, I, Ayuso-Gutierrez, JL, Baldwin, D, Bech, P, Benkert, O, Berk, Michael, Bitter, I, Bourgeois, ML, Burrows, G, Cassano, G, Cetkovich-Bakmans, M, Cookson, JC, Costa, DD, Gheroghe, MD, Heinze, G, Higuchi, T, Hirschfeld, RM, Höschl, C, Holsboer-Trachsler, E, Kasper, S, Katona, C, Keller, MB, Kulhara, P, Kupfer, DJ, Lecrubier, Y, Leonard, B, Licht, RW, Lingjaerde, O, Lublin, H, Mendlewicz, J, Mitchell, P, Paykel, ES, Puzynski, S, Rush, AJ, Rybakowski, JK, Schweitzer, I, Unützer, J, Verstergaard, P, Vieta, E, and Yamada, K

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results